<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="164933">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02065297</url>
  </required_header>
  <id_info>
    <org_study_id>AUDIA-SAMSON HORTON TH17</org_study_id>
    <nct_id>NCT02065297</nct_id>
  </id_info>
  <brief_title>Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)</brief_title>
  <official_title>Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this open, controlled, multicentre biomedical research study is to identify new
      markers specifically associated with Horton's disease. This would make it possible to
      improve the diagnosis and management of this disease.

      Participation consists in taking one or several blood samples depending on the group
      patients/controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Quantification of specific cytokines of the Th17 immune response (IL-17 A and IL-23) in the serum</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Quantification of LTh17 by flow cytometry</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of the activation level of genes specifically involved in Th17 response using RT-PCR on frozen mRNA</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure the ability of Treg to proliferate and to synthesize IL-17 in response to different antigenic stimulations</measure>
    <time_frame>Up to 6 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Horton's Disease</condition>
  <condition>Infectious Disease</condition>
  <condition>Neoplasia</condition>
  <condition>Solid Tumor</condition>
  <condition>Hemopathy</condition>
  <arm_group>
    <arm_group_label>Horton's disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Infectious disease</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoplasia</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>1 blood sample</intervention_name>
    <arm_group_label>Infectious disease</arm_group_label>
    <arm_group_label>Neoplasia</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)</intervention_name>
    <arm_group_label>Horton's disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Horton' s disease Patients with an infectious disease Patients with
        neoplasia ( solid tumor or hemopathy ) Healthy controls
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients

          -  Patients who have provided written informed consent

          -  Patients with national health insurance cover

          -  Age: 50 to 90 years

        Patients with Horton' s disease :

          -  at the diagnosis, before any treatment

          -  or in remission

          -  or in relapse

        Patients with an infectious disease :

          -  Bacteriologically or radiologically confirmed

          -  Presenting an inflammatory syndrome defined by :

          -  CRP ≥ 10 mg / L

          -  and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1

        Patients with neoplasia ( solid tumour or hemopathy ) :

          -  At the diagnosis, before treatment by chemotherapy

          -  Presenting an inflammatory syndrome defined by:

          -  CRP ≥ 10 mg / L

          -  and Fibrinogen ≥ 4 g / L or ESR ≥ 30 mm at H1

        Controls :

        These are healthy volunteers recruited among blood donators at Dijon CHU, voluntary
        hospital personnel ( nurses, doctors and secretaries ), patients at the EPHAD (
        Champmaillot centre for geriatric patients ) and patients without infectious,
        inflammatory, or auto-immune disease ( CRP &lt; 5mg / L ) or cancer recruited from the
        investigating departments of Dijon CHU. They will be matched for age and sex.

          -  Age: 18 - 90 years

          -  Patients with national health insurance cover

          -  who have provided written informed consent

          -  Absence of an inflammatory syndrome ( CRP &lt; 5 mg / L )

        Exclusion Criteria :

          -  Any patient who does not meet the inclusion criteria
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sylvain AUDIA</last_name>
    <phone>3.80.29.34.32</phone>
    <phone_ext>+33</phone_ext>
    <email>sylvain.audia@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de BESANCON</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadine MAGY-BERTRAND</last_name>
      <phone>3 81 66 89 15</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain AUDIA</last_name>
      <phone>3.80.29.34.32</phone>
      <phone_ext>+33</phone_ext>
      <email>sylvain.audia@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de METZ</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François MAURIER</last_name>
      <phone>3 87 39 47 72</phone>
      <phone_ext>+33</phone_ext>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infection</mesh_term>
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
